Trial Search Results

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission following one or two prior pulmonary relapses.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eleison Pharmaceuticals LLC.

Stanford Investigator(s):

Intervention(s):

  • Drug: Inhaled Lipid Cisplatin (ILC)

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. History of osteosarcoma metastatic to the lung(s). (First or second pulmonary
   recurrence(s) removed by surgery, and previous second-line systemic chemotherapy is
   allowed).

   2. Patients must be macroscopically disease free following pulmonary metastectomy of a
   single or multiple lesions. Complete remission surgically (free of macroscopic
   disease) is required. Pleural disruption and/or microscopic positive margins are
   allowed.

   3. Age ≥13 years.

   4. Patients must have recovered sufficiently from all acute adverse effects of prior
   therapies, excluding alopecia.

   5. Patients must have an ECOG performance status of 0-2. (Lansky score of 50-100 if < 16
   years old).

   6. Patients must have recovered sufficiently from surgery and have adequate airflow and
   pulmonary reserve. This decision should be at the investigator's discretion taking
   into consideration pre-surgery pulmonary function. (As a guideline: adequate airflow
   defined by a measured Forced Expiratory Volume (FEV1) not less than 50% of the
   predicted value and adequate pulmonary reserve as evidenced by a FEV1/FVC ratio of 65%
   or greater).

   7. Patients must have adequate renal function as defined by a serum creatinine of ≤ 1.5
   mg/dl.

   8. Patients must have adequate liver function as defined by total bilirubin of ≤ 1.5
   mg/dl and ALT or AST < 2.5 times the institution's upper normal limit.

   9. Patients must have adequate bone marrow function as defined by an absolute neutrophil
   count (ANC) of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3.

10. Signed informed consent including, where applicable, the consent of the patient's
   legal guardian.

Exclusion Criteria:

   1. Current extrapulmonary disease.

   2. Current macroscopic pulmonary lesions.

   3. Greater than 2 pulmonary recurrences.

   4. Greater than 4 weeks since thoracotomy rendering patient free of macroscopic disease.

   5. Females who are pregnant or breast-feeding.

   6. Concomitant disease or condition that could interfere with the conduct of the study,
   or that would, in the opinion of the investigator, pose an unacceptable risk to the
   patient in this study.

   7. Contraindication to or unwillingness to undergo multiple CT scans and chest X-rays.

   8. Unwillingness or inability to comply with the study protocol for any other reason.

   9. Participation in an investigational drug or device study or treatment with any
   anti-neoplastic agent within 14 days of the first day of dosing on this study

Ages Eligible for Study

13 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-497-8953
Not Recruiting